Advertisement

Digestive Diseases and Sciences

, Volume 47, Issue 11, pp 2615–2620 | Cite as

Effect of Lactobacillus plantarum 299v on Colonic Fermentation and Symptoms of Irritable Bowel Syndrome

  • S. Sen
  • M.M. Mullan
  • T.J. Parker
  • J.T. Woolner
  • S.A. Tarry
  • J.O. Hunter
Article

Abstract

A number of recent clinical trials have promoted the use of probiotic bacteria as a treatment for irritable bowel syndrome (IBS). The recent demonstration of abnormal colonic fermentation in some patients with this condition provides an opportunity for the objective assessment of the therapeutic value of these bacteria. This study was designed to investigate the effects of Lactobacillus plantarum 299V on colonic fermentation. We conducted a double-blind, placebo-controlled, cross-over, four-week trial of Lactobacillus plantarum 299V in 12 previously untreated patients with IBS. Symptoms were assessed daily by a validated composite score and fermentation by 24-hr indirect calorimetry in a 1.4-m3 canopy followed by breath hydrogen determination for 3 hr after 20 ml of lactulose. On placebo, the median symptom score was 8.5 [6.25–11.25 interquartile range (IQR)], the median maximum rate of gas production was 0.55 ml/min (0.4–1.1 IQR), and the median hydrogen production was 189.7 ml/24 hr (118.3–291.1 IQR). On Lactobacillus plantarum 299V the median symptom score was 8 (6.75–13.5 IQR), the median maximum rate of gas production 0.92 ml/min (0.45–1.5 IQR), and the median hydrogen production 208.2 ml/24 hr (146–350.9 IQR). There was no significant difference. Breath hydrogen excretion after lactulose was reduced by the probiotic (median at 120 min, 6 ppm; placebo, 17 ppm; P = 0.019). In conclusion, Lactobacillus plantarum 299V in this study did not appear to alter colonic fermentation or improve symptoms in patients with the irritable bowel syndrome.

irritable bowel syndrome colonic fermentation probiotic bacteria 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Alun Jones V, Mclaughlin P, Shorthouse M, Worman E, Hunter JO: Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome. Lancet 2(8308):1115–1117, 1982Google Scholar
  2. 2.
    Nanda R, James R, Smith H, Dudley CR, Jewell DP: Food intolerance and the irritable bowel syndrome. Gut 30:1099–1104, 1989Google Scholar
  3. 3.
    Parker TJ, Naylor SJ, Riordan AM, Hunter JO: Management of patients with food intolerance in irritable bowel syndrome: the development and use of an exclusion diet. J Hum Nutr Diet 8:159–166, 1995Google Scholar
  4. 4.
    Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G: The fecal microbial population in the irritable bowel syndrome. Microbiology 5:185–194, 1982Google Scholar
  5. 5.
    Bayliss CE, Houston AP, Alun-Jones V, et al: Microbiological studies on food intolerance. Proc Nutr Soc 43:16A, 1984Google Scholar
  6. 6.
    Bradley HK, Bayliss CE, Wyatt GM, et al: Food intolerance and microbial populations in the human colon. In Recent Advances in Anaerobic Bacteriology. Dordrecht, Martinus Nij hoff, 1985Google Scholar
  7. 7.
    Bradley HK, Wyatt GM, Bayliss CE, Hunter JO: Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol 23:29–32, 1987Google Scholar
  8. 8.
    King TS, Elia M, Hunter JO: Abnormal colonic fermentation in irritable bowel syndrome. Lancet 352:1187–1189, 1998Google Scholar
  9. 9.
    Johansson M-L, Berggren A, Nobaek S, Nyman M, Bjorck I, Ahrne S, Jeppsson B, Molin G: Survival of Lactobacillus plantarum DSM 9843 and effect on the short chain fatty acid content in faeces after ingestion of ProViva rose-hip drink. Int J Food Microbiol 42:29–38, 1998Google Scholar
  10. 10.
    Mao Y, Nobaek S, Kasravi B, Adawi D, Stenram V, Molin G, Jeppsson B: The effect of Lactobacillus strains and oat fibre on methotrexate-induced enterocolitis in rats. Gastroenterology 111:334–344, 1996Google Scholar
  11. 11.
    Nobaek S, Johansson M-L, Molin G, Ahrne S, Jeppsson B: Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 95:1231–1238, 2000Google Scholar
  12. 12.
    Thompson WG, Creed FH, Drossman DA, et al: Functional bowel disorders and functional abdominal pain. Gastroenterol Int 5:75–91, 1992Google Scholar
  13. 13.
    King TS, Hunter JO: Do symptoms improve with quality of life in IBS? Gut 40(suppl 1):64, 1997(abstract)Google Scholar
  14. 14.
    Schofield WN, Schofield C, James WPT: Predicting basal metabolic rate, new standards and review of previous work. Hum Nutr Clin Nutr 39(suppl):1–96, 1985Google Scholar
  15. 15.
    Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA: Functional bowel disease and functional abdominal pain. Gut 45(suppl II):1143–1147, 1999Google Scholar
  16. 16.
    Klein KB: Controlled treatment trials in irritable bowel syndrome: A critique. Gastroenterology 95:232–241, 1988Google Scholar
  17. 17.
    Everhart JE, Renault PF: Irritable bowel syndrome in office based practice in the United States. Gastroenterology 100:998–1005, 1991Google Scholar
  18. 18.
    Maxwell PR, Mendell MA, Kumar D: Irritable bowel syndrome. Lancet 350:1691–1695, 1997Google Scholar
  19. 19.
    Garcia Rodriguez LA, Ruigomez A: Increased risk of irritable bowel syndrome after bacterial gastroenteritis: a cohort study. BMJ 318:565–566, 1999Google Scholar
  20. 20.
    Alun Jones V, Wilson AJ, Hunter JO, Robinson RE: The aetiological role of antibiotic prophylaxis with hysterectomy in irritable bowel syndrome. J Obstet Gynaecol 5(suppl 1):22–23, 1984Google Scholar
  21. 21.
    Berg RD: Probiotics, prebiotics or “conbiotics”? Trends Microbiol 6:89–92, 1998Google Scholar
  22. 22.
    Guarner F, Schaafsma GJ: Probiotics. Int J Food Microbiol 39:237–238, 1998Google Scholar
  23. 23.
    Malin M, Suomalainen H, Saxelin M, Isolauri E: Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 40:137–145, 1996Google Scholar
  24. 24.
    Bengmark S: Econutrition and health maintenance. A new concept to prevent GI inflammation, ulceration and sepsis. Clin Nutr 15:1–10, 1996Google Scholar
  25. 25.
    Alander M, Satokari R, Korpela R, Suxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, Von Wright A: Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol 65(1):351–354, 1999Google Scholar
  26. 26.
    Batterman RC, Lower WR: Placebo responsiveness–influence of previous therapy. J Curr Ther 10:136–143, 1968Google Scholar
  27. 27.
    Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matheuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis. A double-blind, placebo-controlled trial. Am J Gastroenterol 119:305–309, 2000Google Scholar

Copyright information

© Plenum Publishing Corporation 2002

Authors and Affiliations

  • S. Sen
    • 1
  • M.M. Mullan
    • 1
  • T.J. Parker
    • 1
  • J.T. Woolner
    • 1
  • S.A. Tarry
    • 1
  • J.O. Hunter
    • 1
  1. 1.Department of GastroenterologyAddenbrooke's HospitalCambridgeUK

Personalised recommendations